Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.

Published by: GIR (GlobalInfoResearch)
Catalog: Pharma & Healthcare
Publishing Date: Dec 2016
Single User License: USD 3480
Corporate Users License: USD 4680
Delivery time: 24 hours
Pages: 115
Tables and Figures: 144

Full information ：[url]http://www.globalinforesearch.com/goods.php?id=2623[url]

Scope of the Report:

This report focuses on the Checkpoint Inhibitors for Treating Cancer in Global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

Market Segment by Manufacturers, this report covers
Bristol-Myers Squibb(BMS)
Merck
Roche

Market Segment by Regions, regional analysis covers
North America (USA, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America, Middle East and Africa

Market Segment by Type, covers
PD-1 inhibitors
PD-L1 inhibitors
CTLA-4 inhibitors

Market Segment by Applications, can be divided into
Melanoma treatment
Bladder cancer treatment
Other

There are 13 Chapters to deeply display the global Checkpoint Inhibitors for Treating Cancer market.

Chapter 1, to describe Checkpoint Inhibitors for Treating Cancer Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Checkpoint Inhibitors for Treating Cancer, with sales, revenue, and price of Checkpoint Inhibitors for Treating Cancer, in 2015 and 2016;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Checkpoint Inhibitors for Treating Cancer, for each region, from 2011 to 2016;

Chapter 5, 6, 7 and 8, to analyze the key regions, with sales, revenue and market share by key countries in these regions;

Chapter 9 and 10, to show the market by type and application, with sales market share and growth rate by type, application, from 2011 to 2016;

Chapter 11, Checkpoint Inhibitors for Treating Cancer market forecast, by regions, type and application, with sales and revenue, from 2016 to 2021;

Chapter 12 and 13, to describe Checkpoint Inhibitors for Treating Cancer sales channel, distributors, traders, dealers, appendix and data source.

Betty
Sales Director
E-mail：[email protected]
Tel: HK:00852-58197708 USA:0013479661888
Add: Room 1902 Two International Finance Centre 8 Finance Street, Central Hong Kong
Website: http://www.globalinforesearch.com/goods_all.php